QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Elana Gotkine
MONDAY, Nov. 28, 2022 (HealthDay News) -- For patients with high-risk resected melanoma, adjuvant pembrolizumab improves quality of life (QOL) compared with standard of care with…